Ewa Kalinka-Warzocha
Ewa Kalinka-Warzocha
Unknown affiliation
Verified email at
Cited by
Cited by
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ...
New England journal of medicine 372 (4), 320-330, 2015
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ...
The Lancet 393 (10183), 1819-1830, 2019
Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial
PA Ascierto, GV Long, C Robert, B Brady, C Dutriaux, AM Di Giacomo, ...
JAMA oncology 5 (2), 187-194, 2019
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis
R Duchnowska, R Pęksa, B Radecka, T Mandat, T Trojanowski, B Jarosz, ...
Breast Cancer Research 18 (1), 1-11, 2016
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
P Krawczyk, DM Kowalski, R Ramlau, E Kalinka‑Warzocha, K Winiarczyk, ...
Oncology letters 13 (6), 4433-4444, 2017
MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or …
E Van Cutsem, HJ Lenz, J Furuse, J Tabernero, V Heinemann, T Ioka, ...
Journal of Clinical Oncology 34 (15_suppl), 4007-4007, 2016
The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study
P Krawczyk, R Ramlau, J Chorostowska-Wynimko, T Powrózek, ...
Journal of cancer research and clinical oncology 141 (1), 61-68, 2015
Czerniaki skóry—zasady postępowania diagnostyczno-terapeutycznego w 2016 roku
P Rutkowski, PJ Wysocki, A Nasierowska-Guttmejer, J Fijuth, ...
Onkologia w Praktyce Klinicznej-Edukacja 1 (1), 37-53, 2015
Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma
P Centkowski, L Brydak, M MachaŁa, E Kalinka-Warzocha, ...
Journal of clinical immunology 27 (3), 339-346, 2007
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum-and gemcitabine-based chemotherapy in non-small cell lung cancer patients
R Mlak, P Krawczyk, R Ramlau, E Kalinka-Warzocha, ...
Oncology Reports 30 (5), 2385-2398, 2013
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma …
E Van Cutsem, HJ Lenz, J Furuse, J Tabernero, V Heinemann, T Ioka, ...
Journal of Clinical Oncology 34 (4_suppl), 193-193, 2016
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases
R Duchnowska, J Sperinde, A Chenna, W Huang, JM Weidler, J Winslow, ...
Neuro-oncology 17 (9), 1241-1249, 2015
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
P Krawczyk, T Kucharczyk, DM Kowalski, T Powrózek, R Ramlau, ...
Journal of cancer research and clinical oncology 140 (12), 2047-2057, 2014
Cutaneous melanomas
P Rutkowski, PJ Wysocki, A Nasierowska-Guttmejer, A Jeziorski, ...
Oncol Clin Pract 15 (1), 1-19, 2019
Guidelines for the diagnosis and management of osteoporosis in Poland: Update 2017
R Lorenc, P Głuszko, E Franek, M Jabłoński, M Jaworski, ...
Endokrynologia Polska 68 (5), 604-609, 2017
Ipilimumab—postęp w terapii chorych na zaawansowanego czerniaka
T Świtaj, P Wysocki, M Wojtukiewicz, P Potemski, L Rudnicka, W Bartnik, ...
Onkologia w Praktyce Klinicznej 7 (5), 231-245, 2011
Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non‐Hodgkin's lymphoma
J Nowak, E Kalinka‐Warzocha, P Juszczynski, P Bilinski, ...
Genes, Chromosomes and Cancer 46 (5), 500-507, 2007
Two-year survival and safety update in patients (pts) with treatment-naďve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066
V Atkinson, PA Ascierto, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, ...
Journal of Translational Medicine 14, 2016
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low‐grade B‐cell non …
E Kalinka‐Warzocha, J Wajs, E Lech‐Maranda, B Ceglarek, J Holowiecki, ...
Cancer 113 (2), 367-375, 2008
The system can't perform the operation now. Try again later.
Articles 1–20